v3.26.1
Segment and Related Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment and Related Information Segment and Related Information
We derive revenues through the delivery of test reports for our molecular diagnostic tests. All of our operations are located within the U.S. and our business is focused on the U.S. market.
We have a single reportable segment consisting of a single operating segment.
The measures of segment profit or loss for our single reportable segment were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Net revenues from external customers(1)
$103,546 $86,188 $187,225 $174,176 
Significant segment expenses:
Personnel costs60,349 51,551 118,716 103,751 
Organizational and marketing costs16,029 14,487 31,623 28,716 
Inventory usage8,450 5,458 14,887 10,189 
Clinical studies and publication costs2,103 1,923 4,645 4,008 
Professional services2,669 2,298 5,676 5,874 
Other segment items16,006 5,948 28,260 42,963 
Segment (loss) income$(2,060)$4,523 $(16,582)$(21,325)
(1)For information on disaggregation of segment revenue by type and information about payor concentration, see Note 3.
Other Segment Items
Other segment items include all other operating expenses types, including IT service and software licensing costs, fixed and variable expenses incurred for leasing of facilities and equipment, depreciation and amortization, gain or losses on disposal of fixed assets in the routine course of business, fair value adjustment for equity securities, realized gains or losses on investment securities, administrative costs, expense for use of prepaids, including insurance premiums and warranties for lab equipment, public company costs (less audit fees), interest and other non-operating loss or income, and income tax expense or benefits. Our CODM does not individually review budgets or results for these activities.
Other amounts included in the measure of segment profit or loss were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Interest income$2,356 $2,944 $4,901 $6,043 
Interest expense(193)(21)(327)(38)
Depreciation and amortization4,070 3,414 7,999 33,178 
Income tax expense (benefit)370 (4,666)479 (5,089)
Stock-based compensation expense11,589 11,208 21,365 22,387 
Net (losses) gains on equity securities(630)1,185 1,392 (240)
Total assets for our reportable segment were located in the U.S. and were $561.2 million and $578.6 million as of June 30, 2026 and December 31, 2025, respectively. Expenditures for additions to long-lived assets were $5.6 million and $12.9 million for the three months ended June 30, 2026 and 2025, respectively, and $10.8 million and $18.6 million for the six months ended June 30, 2026, and 2025, respectively.